当前位置：药品说明书与价格首页 >> 综合药讯 >> 喜疗妥治疗浅表血栓性静脉炎疗效卓越

喜疗妥治疗浅表血栓性静脉炎疗效卓越

2009-10-15 14:39:55 作者：新特药房来源：新特药网浏览次数：90 文字大小：【大】【中】【小】

简介： Excellent effects of Hirudoid on superficial thrombophlebitis喜疗妥治疗浅表血栓性静脉炎疗效卓越 Superficial thrombophlebitis must be considered as a risk factor of deep vein thromphlebitis ...

关键字：喜疗妥浅表血栓性静脉炎

Excellent effects of Hirudoid on superficial thrombophlebitis
喜疗妥治疗浅表血栓性静脉炎疗效卓越

Superficial thrombophlebitis must be considered as a risk factor of deep vein thromphlebitis are pain, reddening, swelling and induration. Superficial thrombophlebitis remains a common complication of continuous intravenous infusion. Though the condition is rarely responsible for serious illness, it often causes considerable pain and discomfort at the site of the infusion. The duration of the infusion and the composition of the infusion solution are generally responsible for the occurrence of undesirable side effects.
浅表血栓性静脉炎被认为是深静脉血栓的危险致病因素，以疼痛、充血、水肿和硬化为特征。浅表血栓性静脉炎是持续静脉注射的常见并发症。虽然，很少引起严重的疾病，但是常常引起注射部位的疼痛和不适。注射的持续时间和注射液的成分往往是引起副作用的主要原因。

In the studies performed by Mehta et al. and Schedel et al. using the 125l-fibrinogen test to measure the development of the thrombus it was shown that the clinical symptoms of thrombophlebitis decreased when a regression of the thrombus was achieved.
Mehta 和Schedel等人进行了一系列相关研究，他们用I125标记的纤维蛋白原监测了血栓的变化。研究显示，伴随着血栓的衰退，血栓性静脉炎的症状得到了缓解。

Schedel et al. investigated the efficacy of Hirudoid forte in 40 patients with postoperI bitis under double-blind conditions in comparison to placebo. The parameters pain, reddening (erythema), swelling and induration (palpable cord) and the 125l-fibrinogentest were used as assessment criteria.
Schedel等人研究了特强喜疗妥软膏的疗效，以安慰剂为对照，双盲，受试对象为40位患者。疗效的评估标准包括：疼痛、充血（红斑）、水肿、硬化（可触及的条索）和I125标记的纤维蛋白原。

In the Hirudoid forte group, a continuous decrease of fadioactivity was measured from the first day of treatment until the last day of examination. The placebo group showed a slight increase of activity up to the 5th day. Only then radioactivity began to decline.
在特强喜疗妥软膏组，从用药的第一天起直至检测的最后一天，放射活性持续下降。而安慰剂组直至试验的第五天放射活性仍有轻微的增加，从那以后放射活性才开始下降。

While there was an increase in symptoms up to the third day in the placebo group, the patients treated with Hirudoid Forte observed an immediate and continuous subsidence of the symptoms until the end of therapy on the 6th day. In spite of the relatively small number of patients, the clinical results are relevant because they were confirmed by the results of the fibrinogen test.
安慰剂组直至用药的第三天症状仍在加重，而特强喜疗妥组用药后症状立即减轻并且持续减轻直至第六天治疗结束。尽管受试患者的数量相对较少，该临床研究的结论是可信的，因为其结论通过纤维蛋白原测试得到了进一步论证。

The differences between the two groups were statistically significant from the first (p<0.025) to the 6th (p<0.001 ) day of treatment.
治疗期间组间差异均有统计学差异，第一天为p<0.025，第六天为p<0.001。

In an additional placebo controlled double-blind study the efficacy of Hirudoid cream was assessed in treating superficial thrombophlebitis developing after continuous infusion (Metha et al.). One hundred surgical patients were studied, and clinical examination and the 125I-labelled fibrinogen test used to assess the results.
另外一项安慰剂对照的双盲研究，评估了喜疗妥软膏治疗由于持续注射而引起的浅表血栓性静脉炎的疗效(Metha 等人)。受试对象为100位外科疾病患者，临床检查和I125标记的纤维蛋白原测试用于疗效评估。

When 125I-labelled fibrinogen is injected intravenously it is incorporated into a forming thrombus. Repeated counts of radioactivity over the site of the thrombus and over areas where there are no thrombi allow a quantitative assessment of the fate of the thrombus. The decrease in percentage difference of radioactivity over these two sites indicates the rate of thrombus dissolution.
当I125标记的纤维蛋白原被注射入静脉后就会形成血栓。对血栓部位和非血栓部位进行反复的测试用于定量地检测血栓的变化。两部位放射活性百分比差异的减少提示了血栓的分解率。

The results showed distinct differences in the effects of Hirudoid and placebo cream:
结论直接显示了喜疗妥组和安慰剂组的疗效差异：

The radioactivity disappeared significantly more rapidly from the site of the thrombophlebids in the Hirudoid treated patients compared with those treated with placebo. Furthermore, the disappearance or persistence of local symptoms and signs of the thrombophlebitis closely followed the decline or increase in radio-activity. The difference was statistically significant (p < 0.05).
血栓性静脉炎部位放射活性的消失，喜疗妥治疗组比安慰剂组显著快得多。而且，血栓性静脉炎部位的症状和体症的减轻或持续是与放射活性的下降和增加紧密相关的。差异具有统计学意义(p < 0.05)。

Local or systemic side effects were not observed in any of the cases.
任何病例均未观测到局部或全身副作用。
The great efficacy of Hirudoid forte in comparison to placebo was confirmed in a double blind study in 102 women with postoperative infusion thrombophlebitis (Kowalsky/Budde).
特强喜疗妥制剂对于术后输注性血栓性静脉炎的卓越疗效在一安慰剂对照的双盲研究中得到了论证，受试对象为102位女性患者(Kowalsky/Budde)。

Hirudoid forte and placebo were applied for 10 days. Analgetics and anti-inflammatory agents were not used. Assessment criteria were pain on pressure, oedema and erythema.
特强喜疗妥制剂和安慰剂分别应用了10天。未应用止痛剂和消炎药。评估标准为压痛、水肿和红斑。

During the treatment with Hirudoid forte pain on pressure subsided in 96% of patients, swelling in 98% and erythema in 83%.The differences to the placebo group were statistically significant on the 1%, 10% and 5% levels in pain on pressure, oedema and erythema, respectively.
治疗期间，特强喜疗妥组96％的患者压痛缓解，96％的患者水肿消退，而红斑的减轻率为83％。安慰剂组则分别为1％、10％和5％。组间差异具有统计学意义。

The tolerability was very good in all cases; there were no skin irritation or other side effects.
所有的病例耐受性均非常好，无皮肤刺激或其它副作用。